Concepedia

David Sommerhalder

DS

Statistics

Publications

14

Citations

365

H-Index

11

Active since

2017

Affiliations

Texas Oncology(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

South Texas Accelerated Research Therapeutics

David Sommerhalder is an author at Texas Oncology specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2017–2025

14

Publications

14

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Yuxiang Ma, Yunpeng Yang, Yan Huang et al. · Nature Medicine · 2025 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Pasi A. Jänne, Frédéric Bigot, Kyriakos P. Papadopoulos et al. · Molecular Cancer Therapeutics · 2023 · 56 citations

Medicine, Oncology, Pharmacology +15

Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial

Toru Mukohara, Yeon Hee Park, David Sommerhalder et al. · Nature Medicine · 2024 · 53 citations · Full text

Medicine, Molecular Biology, Oncology +14

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Ignacio Garrido‐Laguna, Brian M. Wolpin, Wungki Park et al. · Journal of Clinical Oncology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +16

Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review

David Sommerhalder, Amol Takalkar, Rodney E. Shackelford et al. · Clinical Case Reports · 2017 · 28 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +11

1–5 of 14